Key result
Timolol lowers blood pressure without significantly reducing cardiac output in hypertensive patients.
Why the study?
Preliminary observations suggested that timolol normalizes cardiac output after 5 weeks in hypertensive patients, unlike propranolol, but confirmation in a larger series was needed.
Does timolol reduce blood pressure without significantly reducing cardiac output in patients with mild essential hypertension?
Does timolol reduce blood pressure without significantly reducing cardiac output in patients with mild essential hypertension?
Timolol effectively lowers blood pressure and heart rate in hypertensive patients without causing a sustained reduction in cardiac output after 5 weeks of treatment.
Answers are grounded in this paper and cite their sources.
Timolol may lower BP and HR without reducing CO in mild hypertension; leaves open confirmation in randomized trials.
Data published by this laboratory indicated that the beta adrenergic blocking drugs timolol and propranolol exerted equivalent beta blocking and antihypertensive actions in patients with mild essential hypertension, but that whereas cardiac output fell acutely with both drugs, it returned to normal after 5 wk of treatment with timolol, but remained depressed after propranolol. This preliminary observation needed further confirmation in a larger series of patients. In this study, 11 patients with initial diastolic blood pressures between 90 and 125 mm Hg were given timolol for 5 wk. Hemodynamic measurements were made before and at the end of treatment. Mean heart rate fell from 76.8 to 64.3 bpm (p less than 0.001), and blood pressure was reduced from 179.4/99 mm Hg to 167.4/93.3 mm Hg (less than 0.02). Cardiac output averaged 6.29 L/min before timolol, and fell to 5.95 L/min (NS) after treatment. Stroke volume increased significantly, while total peripheral resistance was unchanged. These results confirm our earlier observations that timolol is an effective beta adrenergic blocking drug with antihypertensive action that does not reduce cardiac output significantly when given chronically. This drug merits further evaluation in other cardiovascular disorders since it may have advantages over other beta adrenergic blocking drugs.
No takes yet. Share an insight, caveat, or question.
Franciosa et al. (1975) studied mild essential hypertension (n=11). Timolol vs. Baseline was evaluated on Cardiac output (p=NS). Timolol treatment for 5 weeks in hypertensive patients reduced blood pressure but did not reduce cardiac output.
Synapse has enriched 10 related papers. Consider them for comparative context: